Recruiting
Molecular Biomarkers of Response to Radiation Therapy in Breast Cancer
The purpose of this study is to identify potential genetic and other molecular biomarkers of response to radiation therapy in breast cancer that may help to personalize breast cancer radiation treatment in the future.
ClinicalTrials.gov IDNCT06648148
PhaseNot Applicable
Enrollment200
SponsorInstitute of Oncology Ljubljana
Age18 Years
SexFEMALE
Conditions studied
Breast Cancer, Radiotherapy Side Effect
About this study
The purpose of this study is to identify potential genetic and other molecular biomarkers of response to radiation therapy in breast cancer that may help to personalize breast cancer radiation treatment in the future.
Primary outcomes
- Adverse events of radiation therapy (Within 1 month after completion of radiotherapy)
- Adverse events of radiation therapy (6 months after radiotherapy)
- Adverse events of radiation therapy (2 years after radiotherapy)
- Adverse events of radiation therapy (5 years after radiotherapy)
Eligibility information
Inclusion Criteria:
* Breast cancer patients with DCIS with an indication for adjuvant radiation therapy
Exclusion Criteria:
* Any specific systemic oncological therapy
Study locations
- Institute of Oncology Ljubljana, Ljubljana, 1000 Slovenia
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.